Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Kidney
Descriptor: Poor Prognosis

Reference Number: 493
Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH. MET expression in sporadic renal cell carcinomas. J Korean Med Sci. 21, 672-7 (2006)
PubMed link      E-mail link

Reference Number: 539
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 98, 491-8 (2007)
PubMed link      E-mail link

Reference Number: 670
Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M, Kanayama HO. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest. 55, 106-11 (2008)
PubMed link      E-mail link

Reference Number: 1336
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24, 343-9 (2013)
PubMed link      E-mail link